Vasso Apostolopoulos, PhD Professor

Email: vasso@scientist.com


    Vasso Apostolopoulos - Latest News
Website Designed by www.SevenStarWebsites.com™  Copyright ©  2011-2014

Katsara, M., Grigoriadis, N., Yuriev, E., Ramsland, P.A., Deraos, G., Matsoukas, J. and Apostolopoulos, V. Helani Congress, Athens, Greece, October 2013. Mannosylation of mutated MBP83-99 peptides diverts immune responses from Th1 to Th2 in SJL/J mice: Bioactive peptides for Multiple Sclerosis
LATEST CONFERENCE POSTER PRESENTATIONS

Perera, C.J., Zahrooni, S., Apostolopoulos, V. and Moalem-Taylor, G. 4th International congress on neuropathic pain: The pain to relief starts with understanding. Toronto, Canada. May 2013. Immunisation with myelin-derived altered peptide ligands inhibits neuropathic pain following peripheral nerve injury
Perera, C.J., Zahrooni, S., Apostolopoulos, V. and Moalem-Taylor, G. Australian Neuroscience Society, Melbourne Australia. February 2013. Vaccination for neuropathic pain following peripheral nerve injury
LATEST PUBLICATIONS


Kong, Y.Y., Fuchsberger, M., Xiang, S.D., Apostolopoulos, V. and Plebanski, M. Myeloid-Derived Suppressor Cells and their role in diseases. Current Medicinal Chemistry, 20(11):1437-1444, 2013. [Corresponding author].ong, Y.Y., Fuchsberger, M., Xiang, S.D., Apostolopoulos, V. and Plebanski, M. Myeloid-Derived Suppressor Cells and their role in diseases. Current Medicinal Chemistry, 20(11):1437-1444, 2013. [Corresponding author]. PubMed

Apostolopoulos, VInterview. Cancer Vaccines: Looking to the future. Expert Review of Vaccines, 12(10):1125-1126, 2013. [Invited]. PDF



Gartlan, K.H., Wee, J.L., DeMaria, M.C., Nastovska, R., Chang, T.M., Jones, E.L., Apostolopoulos, V., Pietersz, G.A., Hickey, M.J., van Spriel, A.B. and Wright, M.D. Tetraspanin CD37 contributes to the initiation of cellular immunity by promoting dendritic cell migration. European Journal of Immunology, 43(5):1208-1219, 2013. PDF

Cover Image on EJI of Gartlan et al article: The cover features a digitally-coloured scanning electron microscopy image of CD37-deficient dendritic cells (DCs) stimulated with lipopolysaccharide. The image is taken from the article by Gartlan et al. (pp. 1208–1219) in which the authors show that DC adherence to fibronectincoated coverslips is impaired in the absence of the tetraspanin CD37. Gartlan et al. further show that ablation of CD37 in mice also impairs DC migration from skin to draining lymph nodes, chemotactic migration and priming of naive T cells. Together, these findings support a role for CD37 in cellular immunity by promoting DC migration.  Well Done Kate on excellent work and for the cover of EJI......!
Sheng, K.C., Day, S., Wright, M.D., Stojanovska, L. and Apostolopoulos, V. Enhanced dendritic cell-mediated antigen-specific CD4+ T cell responses: IFN-gamma aids TLR stimulation. Journal of Drug Delivery, Volume 2013, Article ID 516749, Epub May 28 2013. [Corresponding author]. PDF

Apostolopoulos, V., Thalhammer, T., Tzakos, A.G. and Stojanovska, L. Targeting antigens to dendritic cell receptors for vaccine development, Volume 2014, Article ID869718, Epub October 2013. [Corresponding author]. PDF

Tian, D.H., Perera, C.J., Apostolopoulos, V. and Moalem-Taylor, G. Effects of vaccination with altered peptide ligand on chronic pain in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. Frontiers in Neurology – Multiple Sclerosis and Neuroimmunology. 4(168):1-8, October 2013. PDF
Molecular model of APL peptide MBP85-96 [Y91] in complex with MHC class II H2 I-As. From Katsara and Apostolopoulos et al.,
Schematic representation of MBP83-99 peptide in complex with HLA-DR2. From Katsara and Apostolopoulos et al.,
Crystal structure of MHC class I in complex with peptide and TcR. From Lazoura and Apostolopoulos et al.,
Structure of MUC1 GalNAc peptide in complex with MHC class I. From Lazoura and Apotolopoulos et al.,
Novel Oncology Therapeutics: Targeted Drug Delivery for Cancer

Guest Editors: 
Andreas Tzakos, Evangelos Briasoulis, Theresia Thalhammer, Walter Jäger, Vasso Apostolopoulos 
12 Articles and 1 Editorial, October 2013. Link
GUEST EDITOR, Special Issue
Editorial. Tzakos, A..G., Briasoulis, E., Thalhammer, T., Jager, W. and Apostolopoulos, V. Novel Oncology Therapeutics: targeted drug delivery for cancer. Journal of Drug Delivery, Volume 2013, Article ID 918304, Epub October 2013. PDF
Vassilaros, S., Tsibanis, A., Tsikkinis, A., McKenzie, I.F.C and Apostolopoulos, V. Up to 15 year clinical follow-up of pilot phase III immunotherapy study in stage II breast cancer patients using oxidised mannan-MUC1. Immunotherapy, 5(11):1177-1182, 2013. PDF
CONFERENCE ORGANISING COMMITTEE
Apostolopoulos, V., is part of the organising committee for - BIT's 6th annual world congress of Vaccines, 2014. 

International Conference Centre, Dalian China, 
April 25-28, 2014
CONFERENCE INVITATIONS

Plenary Speaker (April 2014). 15th International Conference in Medicinal Chemistry: Drug Discovery and Design, Conference. University of Patras, Dept of Chemistry and Pharmacology. Patras, Greece.
Development of an ovarian / breast cancer vaccine: what have we learnt in the last 20 years

Welcome Address (April 2014). 2nd National Conference of the Peloponnese: Developmental Prospects for Western Greece. Rio, Greece
Where is Greece heading where are they going, what needs to be done



OTHER, ORAL PRESENTATIONS

Speaker (March 2014). Biomedical and Lifestyle Diseases (BioLED) Research Unit, Victoria University, VIC Australia.
Immunotherapy in the last 20 years, what have we learnt

Speaker (April 2014). Western Centre for Health Research and Education (WCHRE), Sunshine Hospital VIC Australia
Research, technologies and new collaborative outcomes

Speaker (May 2014). Institute of Sport Exercise and Active Living (ISEAL), Victoria University Footscray Campus, VIC Australia.
Exercise and Immunology: their importance in health and disease

Invited Speaker (invited, accepted, July 2014). Western Buddies Breast Cancer Support Group. ISIS Primary Care, VIC Australia.
'Development of a breast cancer vaccine: what have we learnt in the last 20 years'
'Exercise to treat breast cancer'



LATEST APPOINTMENTS

Biomedical and Lifestyle Diseases (BioLED), Research Member. Victoria University (December 2013 - Present). Link
Editorial Advisory Board. UK Journal of Pharmaceutical and Biosciences (January 2014 - Present). Link
International Advisory Board. Genexine Inc., (April 2014 - Present). Link
Editorial Advisory Board. Biomed Research International (Immunology subject area) (May 2014 - Present). Link

Stojanovska, L. and Apostolopoulos, V. Trick or treat? Alternative therapies for menopause. The Conversation, Published 13 February 2014, Article No. 18007, 2014. Link
IN THE MEDIA
Breast cancer Vaccine developed by Australian scientists can stop disease returning. Channel 7 news, 13 February 2014
Printed script from 7news website. 
[http://www.news.com.au/lifestyle/health/breast-cancer-vaccine-developed-by-australian-scientists-can-stop-disease-returning/story-fneuz9ev-1226826564070] PDF
Article based on publication: Vassilaros, S., Tsibanis, A., Tsikkinis, A., Pietersz, G.A., McKenzie, I.F.C and Apostolopoulos, V. Up to 15 year clinical follow-up of pilot phase III immunotherapy study in stage II breast cancer patients using oxidised mannan-MUC1. Immunotherapy, 5(11):1177-1182, 2013. PDF
Channel 7 News, 13 Feb 2014
Δύο ιερά «τέρατα» της έρευνας για τον καρκίνο στην Ελλάδα  LINK

OnMedgr, 15 April 2014
Η Ελλαδα χανει τα μυαλα τηs PDF
Peloponnisos, 22 April 2014
Simvoulos Epihirision, 04 April 2014
Get Full article here, PDF
Trick or Treat.?
PDF

NeosKosmos
26 March 2014
Stojanovska, L., Apostolopoulos, V., Polman, R. and Borkoles, E. To exercise, or, not to exercise, during menopause and beyond. Maturitas, 77(4):318-323, 2014. PDF
Apostolopoulos, V. 5th Australasian vaccines and immunotherapeutics development (AVID) meeting. Melbourne VIC Australia, May 2014. Clinical study in stage II breast cancer patients using oxidised mannan-MUC1: clinical data 16.5 years on